OBSERVATIONS ON THE EFFECTS OF ALKYLATING AGENTS IN HUMAN NEOPLASTIC DISEASE
Authors: B E HALL, F M WILLETT, D R HALES
Journal: Annals of Internal Medicine (1960)

Article1 March 1960OBSERVATIONS ON THE EFFECTS OF ALKYLATING AGENTS IN HUMAN NEOPLASTIC DISEASEBYRON E. HALL, M.D., F.A.C.P., FORREST M. WILLETT, M.D., F.A.C.P., DONALD R. HALES, M.D.BYRON E. HALL, M.D., F.A.C.P.Search for more papers by this author, FORREST M. WILLETT, M.D., F.A.C.P.Search for more papers by this author, DONALD R. HALES, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-3-602 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the last few years, evaluation at the clinical level of the growth-inhibiting properties of various chemotherapeutic agents has demonstrated the lack of an easily definable pattern with which to predict what degree of growth-inhibitory action may be shown by any given compound under investigation among the broad spectrum of the neoplastic diseases. It is known that tissues with rapid rates of growth are more susceptible to injury by chemical compounds than are those with relatively slow rates of growth, but this generalization applies to normal tissues as readily as it does to malignant tissues. For example, the hemopoietic tissues...Bibliography1. EverettRobertsRoss JLJRWC: Aryl-2 habgenoalkylamines. Part XII. Some carboxylic derivatives of NN-Di-2-chloroethylaniline, J. Chem. Soc., London, p. 2386, 1953. CrossrefGoogle Scholar2. GaltonIsraelsNabarroTill DALGJDM: Clinical trials with p-(di-2-chloroethylamino)-phenylbutyric acid (C. B. 1348) in malignant lymphoma, Brit. M. J. 2: 1172, 1955. CrossrefMedlineGoogle Scholar3. BergelStock FJA: Cytotoxic amino acids and peptides, Ann. Rep. Brit. Empire Cancer Campaign 31: 6, 1953. Google Scholar4. Luck JM: Action of p-(di(2-chloroethyl))-amino-L-phenylalanine on Harding-Passey mouse melanoma, Science 123: 984, 1956. CrossrefMedlineGoogle Scholar5. GellhornKligermanJaffe AMMI: Triethylene melamine in clinical cancer chemotherapy, Am. J. Med. 13: 428-431 (Oct.) 1952. CrossrefMedlineGoogle Scholar6. SykesRundlesPierceKarnofsky MPRWVKDA: Triethylene melamine in management of far advanced ovarian cancer, Surg., Gynec. and Obst. 101: 133-140, 1955. MedlineGoogle Scholar7. SchellHall RFBE: Experience with triethylene melamine (TEM) and triethylene thiophosphoramide (Thio-Tepa) in recurrent or metastatic solid tumors, Surg., Gynec. and Obst. 106: 459-465 (Apr.) 1958. MedlineGoogle Scholar8. ShaySun HDC: Clinical studies of triethylene thiophosphoramide in the treatment of inoperable cancer, Cancer 8: 498-511 (May-June) 1955. CrossrefMedlineGoogle Scholar9. Domagk G: Histologic changes in experimental and human malignant tumours after treatment with cytostatic agents, German M. Month. 1: 133-136, 1956. Google Scholar10. WolfGerlich HJN: Use of ethyleniminoquinones in treatment of human cancer, German M. Month. 1: 137, 1956. Google Scholar11. Brunschwig A: Experiences with E-39 in the treatment of advanced malignant neoplasms, Cancer 11: 765-768 (July-Aug.) 1958. CrossrefMedlineGoogle Scholar12. HaddowTimmis AGM: Myleran in chronic myeloid leukemia. Chemical constitution and biological action, Lancet 1: 207-208, 1953. CrossrefGoogle Scholar13. Galton DA: Myleran in chronic myeloid leukemia, Lancet 1: 208-212, 1953. CrossrefGoogle Scholar14. ReynoldsSchulteMillerHallHales LRTLCFBEDR: Experiences with triethylene thiophosphoramide in advanced carcinoma of the urinary bladder, Proc. Am. A. Cancer Res. 3: 56 (Mar.) 1959. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: San Francisco, California*Received for publication July 21, 1959.Presented at the Fortieth Annual Session of The American College of Physicians, Chicago, Illinois, April 22, 1959.From the Department of Medicine, Stanford University School of Medicine, and the San Francisco Veterans Administration Hospital.†This investigation was supported by a research grant from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.Requests for reprints should be addressed to Byron E. Hall, M.D., 909 Hyde Street, San Francisco, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySystemische Chemotherapie maligner MelanomeChemotherapy of melanomaComparison of the combination of 1, 3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-l-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanomaMelphalanALKYLATING AGENTSLiver Damage After Chemotherapy for Leukemia and LymphomaDissemination of Bladder Neoplasms by Endoscopic Electroresection 1 March 1960Volume 52, Issue 3Page: 602-625KeywordsChemotherapeutic agentsGratitudeHospital medicineLymphomaPalliative careResearch grantsRivers ePublished: 1 December 2008 Issue Published: 1 March 1960 PDF downloadLoading ...